These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 23857664)

  • 21. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
    Corbett EJM; Pentony P; McGill NW
    Int J Rheum Dis; 2017 Jul; 20(7):894-897. PubMed ID: 28205336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A joint effort over a period of time: factors affecting use of urate-lowering therapy for long-term treatment of gout.
    Richardson JC; Liddle J; Mallen CD; Roddy E; Hider S; Prinjha S; Ziebland S
    BMC Musculoskelet Disord; 2016 Jun; 17():249. PubMed ID: 27267878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
    Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN).
    Dalbeth N; Bardin T; Doherty M; Lioté F; Richette P; Saag KG; So AK; Stamp LK; Choi HK; Terkeltaub R
    Nat Rev Rheumatol; 2017 Sep; 13(9):561-568. PubMed ID: 28794514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
    Dalbeth N; House ME; Horne A; Petrie KJ; McQueen FM; Taylor WJ
    BMC Musculoskelet Disord; 2012 Sep; 13():174. PubMed ID: 22978848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
    Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
    J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive dietary education in treated gout patients does not further improve serum urate.
    Holland R; McGill NW
    Intern Med J; 2015 Feb; 45(2):189-94. PubMed ID: 25495503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of gout by UK rheumatologists: a British Society for Rheumatology national audit.
    Roddy E; Packham J; Obrenovic K; Rivett A; Ledingham JM
    Rheumatology (Oxford); 2018 May; 57(5):826-830. PubMed ID: 29447370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The management of gout at an academic healthcare center in Beijing: a physician survey.
    Fang W; Zeng X; Li M; Chen LX; Schumacher HR; Zhang F
    J Rheumatol; 2006 Oct; 33(10):2041-9. PubMed ID: 17014019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Knowledge and practice in the management of asymptomatic hyperuricemia among primary health care physicians in Jeddah, Western Region of Saudi Arabia.
    Alqarni NA; Hassan AH
    Saudi Med J; 2018 Dec; 39(12):1218-1225. PubMed ID: 30520504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of a urate lowering regimen in primary gout.
    Bailén R; González Senac NM; López MM; Llena ML; Migoya M; Rodríguez MT; de Miguel E; Torres RJ; Puig JG
    Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):174-80. PubMed ID: 24940666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GOSPEL 3: Management of gout by primary-care physicians and office-based rheumatologists in France in the early 21st century - comparison with 2006 EULAR Recommendations.
    Goossens J; Lancrenon S; Lanz S; Ea HK; Lambert C; Guggenbuhl P; Saraux A; Delva C; Sahbane S; Lioté F
    Joint Bone Spine; 2017 Jul; 84(4):447-453. PubMed ID: 28411137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gout, urate-lowering therapy, and uric acid levels among adults in the United States.
    Juraschek SP; Kovell LC; Miller ER; Gelber AC
    Arthritis Care Res (Hoboken); 2015 Apr; 67(4):588-92. PubMed ID: 25201123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
    Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares.
    Choi HJ; Lee CH; Lee JH; Yoon BY; Kim HA; Suh CH; Choi ST; Song JS; Joo HY; Choi SJ; Lee JS; Shin KC; Baek HJ
    Int J Rheum Dis; 2017 Apr; 20(4):497-503. PubMed ID: 25160939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring and Achievement of Target Serum Urate Among Gout Patients Receiving Long-Term Urate-Lowering Therapy in the American College of Rheumatology RISE Registry.
    Hammam N; Li J; Kay J; Izadi Z; Yazdany J; Schmajuk G
    Arthritis Care Res (Hoboken); 2023 Jul; 75(7):1544-1552. PubMed ID: 36039961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift.
    Khanna P; Khanna D; Storgard C; Baumgartner S; Morlock R
    Postgrad Med; 2016 Jan; 128(1):34-40. PubMed ID: 26578028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.